Published in Nat Med on January 01, 2001
Ketamine for Thrombolysis in Acute Ischemic Stroke (KETA) | NCT02258204
Glial and neuronal control of brain blood flow. Nature (2010) 6.61
The science of stroke: mechanisms in search of treatments. Neuron (2010) 6.14
LRP: a multifunctional scavenger and signaling receptor. J Clin Invest (2001) 5.31
Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med (2008) 3.64
Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest (2003) 3.41
Stress duration modulates the spatiotemporal patterns of spine formation in the basolateral amygdala. Proc Natl Acad Sci U S A (2005) 2.59
Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis (2010) 1.90
Tissue plasminogen activator is a potent activator of PDGF-CC. EMBO J (2004) 1.79
Hepatocyte growth factor attenuates liver fibrosis induced by bile duct ligation. Am J Pathol (2006) 1.76
The neurovascular unit and combination treatment strategies for stroke. Trends Pharmacol Sci (2012) 1.66
Tissue plasminogen activator and plasminogen mediate stress-induced decline of neuronal and cognitive functions in the mouse hippocampus. Proc Natl Acad Sci U S A (2005) 1.59
Permissive proteolytic activity for visual cortical plasticity. Proc Natl Acad Sci U S A (2002) 1.55
Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice. Blood (2015) 1.53
Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors. Proc Natl Acad Sci U S A (2005) 1.45
Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent. J Clin Invest (2002) 1.44
Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1. J Neurosci (2008) 1.33
Tissue-type plasminogen activator regulates the neuronal uptake of glucose in the ischemic brain. J Neurosci (2012) 1.31
Tissue-type plasminogen activator is a neuroprotectant in the mouse hippocampus. J Clin Invest (2010) 1.30
Key role of tissue plasminogen activator in neurovascular coupling. Proc Natl Acad Sci U S A (2008) 1.30
Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. CNS Neurol Disord Drug Targets (2008) 1.24
Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost (2005) 1.23
Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function. J Neurochem (2008) 1.21
Matrix metalloproteinase-7 disrupts dendritic spines in hippocampal neurons through NMDA receptor activation. J Neurochem (2006) 1.19
uPA modulates the age-dependent effect of brain injury on cerebral hemodynamics through LRP and ERK MAPK. J Cereb Blood Flow Metab (2008) 1.18
Tissue plasminogen activator promotes the effects of corticotropin-releasing factor on the amygdala and anxiety-like behavior. Proc Natl Acad Sci U S A (2004) 1.15
Tissue plasminogen activator and NMDA receptor cleavage. Nat Med (2003) 1.14
Experimental models, neurovascular mechanisms and translational issues in stroke research. Br J Pharmacol (2007) 1.14
Tissue-type plasminogen activator protects neurons from excitotoxin-induced cell death via activation of the ERK1/2-CREB-ATF3 signaling pathway. Mol Cell Neurosci (2012) 1.14
Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism. J Neurochem (2009) 1.12
Tissue-type plasminogen activator has a neuroprotective effect in the ischemic brain mediated by neuronal TNF-α. J Cereb Blood Flow Metab (2011) 1.12
Cerebral blood flow alteration in neuroprotection following cerebral ischaemia. J Physiol (2011) 1.11
Plasminogen activators promote excitotoxicity-induced retinal damage. FASEB J (2005) 1.11
A novel approach for imaging brain-behavior relationships in mice reveals unexpected metabolic patterns during seizures in the absence of tissue plasminogen activator. Neuroimage (2007) 1.10
Transforming growth factor-beta and ischemic brain injury. Cell Mol Neurobiol (2003) 1.10
uPA impairs cerebrovasodilation after hypoxia/ischemia through LRP and ERK MAPK. Brain Res (2008) 1.09
Tissue plasminogen activator prevents white matter damage following stroke. J Exp Med (2011) 1.03
Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation. EMBO J (2005) 1.02
Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activation. J Cereb Blood Flow Metab (2009) 1.02
The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke. BMC Neurol (2014) 1.02
tPA contributes to impaired NMDA cerebrovasodilation after traumatic brain injury through activation of JNK MAPK. Neurol Res (2011) 1.01
Exercise influences hippocampal plasticity by modulating brain-derived neurotrophic factor processing. Neuroscience (2011) 1.01
Deleterious effects of plasminogen activators in neonatal cerebral hypoxia-ischemia. Am J Pathol (2008) 1.01
In vivo bradykinin B2 receptor activation reduces renal fibrosis. J Clin Invest (2002) 1.01
An endoplasmic reticulum retention signal located in the extracellular amino-terminal domain of the NR2A subunit of N-Methyl-D-aspartate receptors. J Biol Chem (2009) 1.00
Blood-brain barrier permeability and tPA-mediated neurotoxicity. Neuropharmacology (2010) 1.00
The tissue plasminogen activator-plasmin system participates in the rewarding effect of morphine by regulating dopamine release. Proc Natl Acad Sci U S A (2004) 1.00
The serine protease plasmin cleaves the amino-terminal domain of the NR2A subunit to relieve zinc inhibition of the N-methyl-D-aspartate receptors. J Biol Chem (2009) 0.99
Optimal dose of aprotinin for neuroprotection and renal function in a piglet survival model. J Thorac Cardiovasc Surg (2009) 0.99
Inhibition of plasminogen activators attenuates the death of differentiated retinal ganglion cells and stabilizes their neurite network in vitro. Invest Ophthalmol Vis Sci (2007) 0.99
Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence. J Cereb Blood Flow Metab (2011) 0.99
The contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: a review of rtPA neurotoxicity. J Cereb Blood Flow Metab (2010) 0.99
Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of tPA For treatment of CNS ischemic disorders. J Neurochem (2010) 0.98
Safety and efficacy of alteplase in the treatment of acute ischemic stroke. Vasc Health Risk Manag (2009) 0.98
Unveiling an exceptional zymogen: the single-chain form of tPA is a selective activator of NMDA receptor-dependent signaling and neurotoxicity. Cell Death Differ (2012) 0.98
Annexin A2: a tissue plasminogen activator amplifier for thrombolytic stroke therapy. Stroke (2010) 0.98
LRP1 assembles unique co-receptor systems to initiate cell signaling in response to tissue-type plasminogen activator and myelin-associated glycoprotein. J Biol Chem (2013) 0.97
Purkinje neuron degeneration in nervous (nr) mutant mice is mediated by a metabolic pathway involving excess tissue plasminogen activator. Proc Natl Acad Sci U S A (2006) 0.97
Reduction of hippocampal cell death and proteolytic responses in tissue plasminogen activator knockout mice after transient global cerebral ischemia. Neuroscience (2007) 0.97
Does inhibiting Sur1 complement rt-PA in cerebral ischemia? Ann N Y Acad Sci (2012) 0.96
Fingolimod reduces hemorrhagic transformation associated with delayed tissue plasminogen activator treatment in a mouse thromboembolic model. Stroke (2013) 0.96
Modulation of NR2B-regulated contextual fear in the hippocampus by the tissue plasminogen activator system. Proc Natl Acad Sci U S A (2007) 0.96
Modulation of acid-sensing ion channels: molecular mechanisms and therapeutic potential. Int J Physiol Pathophysiol Pharmacol (2011) 0.96
Tissue-type plasminogen activator as a therapeutic target in stroke. Expert Opin Ther Targets (2008) 0.95
MMP-7 cleaves the NR1 NMDA receptor subunit and modifies NMDA receptor function. FASEB J (2008) 0.95
Regulation of airway contractility by plasminogen activators through N-methyl-D-aspartate receptor-1. Am J Respir Cell Mol Biol (2010) 0.93
Augmentation of M-type (KCNQ) potassium channels as a novel strategy to reduce stroke-induced brain injury. J Neurosci (2015) 0.93
Xenon is an inhibitor of tissue-plasminogen activator: adverse and beneficial effects in a rat model of thromboembolic stroke. J Cereb Blood Flow Metab (2010) 0.92
Tissue plasminogen activator modulates the cellular and behavioral response to cocaine. Proc Natl Acad Sci U S A (2009) 0.92
Edaravone (Radicut), a free radical scavenger, is a potentially useful addition to thrombolytic therapy in patients with acute ischemic stroke. Biomed Rep (2012) 0.91
Glucagon protects against impaired NMDA-mediated cerebrovasodilation and cerebral autoregulation during hypotension after brain injury by activating cAMP protein kinase A and inhibiting upregulation of tPA. J Neurotrauma (2011) 0.91
Extracellular matrix control of dendritic spine and synapse structure and plasticity in adulthood. Front Neuroanat (2014) 0.89
A Smoothened receptor agonist is neuroprotective and promotes regeneration after ischemic brain injury. Cell Death Dis (2014) 0.89
Protein S blocks the extrinsic apoptotic cascade in tissue plasminogen activator/N-methyl D-aspartate-treated neurons via Tyro3-Akt-FKHRL1 signaling pathway. Mol Neurodegener (2011) 0.88
Acid-sensing ion channels in pathological conditions. Adv Exp Med Biol (2013) 0.87
tPA-S481A prevents neurotoxicity of endogenous tPA in traumatic brain injury. J Neurotrauma (2012) 0.87
Plasmin-mediated degradation of laminin gamma-1 is critical for ethanol-induced neurodegeneration. Biol Psychiatry (2009) 0.87
Ventral striatal plasticity and spatial memory. Proc Natl Acad Sci U S A (2010) 0.87
Age and albumin D site-binding protein control tissue plasminogen activator levels: neurotoxic impact. Brain (2009) 0.87
Identification of a novel targeting sequence for regulated secretion in the serine protease inhibitor neuroserpin. Biochem J (2007) 0.87
Tissue-type plasminogen activator is a neuroprotectant in the central nervous system. Front Cell Neurosci (2015) 0.87
A mental retardation gene, motopsin/neurotrypsin/prss12, modulates hippocampal function and social interaction. Eur J Neurosci (2009) 0.86
Tissue-type plasminogen activator mediates neuronal detection and adaptation to metabolic stress. J Cereb Blood Flow Metab (2013) 0.86
Activation of the epidermal growth factor signalling pathway by tissue plasminogen activator in pancreas cancer cells. Gut (2007) 0.86
Stroke patients develop antibodies that react with components of N-methyl-D-aspartate receptor subunit 1 in proportion to lesion size. Stroke (2013) 0.86
Salvinorin A administration after global cerebral hypoxia/ischemia preserves cerebrovascular autoregulation via kappa opioid receptor in piglets. PLoS One (2012) 0.86
Endothelial cells and astrocytes: a concerto en duo in ischemic pathophysiology. Int J Cell Biol (2012) 0.86
Novel plasminogen activator inhibitor-1-derived peptide protects against impairment of cerebrovasodilation after photothrombosis through inhibition of JNK MAPK. Am J Physiol Regul Integr Comp Physiol (2010) 0.85
One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke. Curr Neuropharmacol (2017) 0.84
tPA regulates pulmonary vascular activity through NMDA receptors. Am J Physiol Lung Cell Mol Physiol (2011) 0.84
PAI-1-derived peptide EEIIMD prevents impairment of cerebrovasodilation by augmenting p38 MAPK upregulation after cerebral hypoxia/ischemia. Am J Physiol Heart Circ Physiol (2010) 0.84
Management of non-traumatic intraventricular hemorrhage. Neurosurg Rev (2012) 0.84
Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute ischemic stroke: minocycline. Pharmacotherapy (2010) 0.84
Tissue plasminogen activator-mediated PDGF signaling and neurovascular coupling in stroke. J Thromb Haemost (2009) 0.83
Tissue plasminogen activator and seizures: a clot-buster's secret life. J Clin Invest (2002) 0.83
Vascular protection to increase the safety of tissue plasminogen activator for stroke. Curr Pharm Des (2012) 0.83
Recombinant tissue plasminogen activator enhances microglial cell recruitment after stroke in mice. J Cereb Blood Flow Metab (2014) 0.83
Association between neuroserpin and molecular markers of brain damage in patients with acute ischemic stroke. J Transl Med (2011) 0.83
Physiological and pathological roles of tissue plasminogen activator and its inhibitor neuroserpin in the nervous system. Front Cell Neurosci (2015) 0.83
Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J (1998) 10.01
In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nat Med (2001) 5.54
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med (1999) 4.85
Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet (2001) 4.66
Molecular mechanisms of blood vessel growth. Cardiovasc Res (2001) 3.94
A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab (1999) 3.25
Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med (2001) 2.66
Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler Thromb Vasc Biol (1999) 2.56
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med (1998) 2.54
Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost (2003) 2.49
Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome. Nat Med (2001) 2.46
Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects. Proc Natl Acad Sci U S A (2001) 2.42
Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation (1995) 2.38
Low levels of tissue factor are compatible with development and hemostasis in mice. J Clin Invest (1998) 2.19
VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat Med (2000) 2.13
Transcription factor hepatocyte nuclear factor 6 regulates pancreatic endocrine cell differentiation and controls expression of the proendocrine gene ngn3. Mol Cell Biol (2000) 2.11
Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation (1999) 1.97
The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol (2001) 1.94
A novel role for VEGF in endocardial cushion formation and its potential contribution to congenital heart defects. Development (2001) 1.92
PR39, a peptide regulator of angiogenesis. Nat Med (2000) 1.90
Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. Blood (1998) 1.81
Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci U S A (1996) 1.66
Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. FASEB J (2008) 1.62
The concept of coupling blood flow to brain function: revision required? Ann Neurol (1987) 1.58
Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest (1998) 1.55
Mice lacking the gene encoding tissue-type plasminogen activator show a selective interference with late-phase long-term potentiation in both Schaffer collateral and mossy fiber pathways. Proc Natl Acad Sci U S A (1996) 1.54
Generation and characterization of urokinase receptor-deficient mice. J Clin Invest (1996) 1.54
Mice lacking factor VII develop normally but suffer fatal perinatal bleeding. Nature (1997) 1.50
Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol (1998) 1.48
A mouse model for Zellweger syndrome. Nat Genet (1997) 1.43
Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain. Glia (2000) 1.41
The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer (2008) 1.41
The quantification of cerebral infarction following focal ischemia in the rat: influence of strain, arterial pressure, blood glucose concentration, and age. J Cereb Blood Flow Metab (1988) 1.39
Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J Exp Med (1997) 1.38
Effects of acutely induced hypertension in cats on pial arteriolar caliber, local cerebral blood flow, and the blood-brain barrier. Circ Res (1976) 1.35
Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction. Am J Pathol (2000) 1.33
Tissue factor deficiency causes cardiac fibrosis and left ventricular dysfunction. Proc Natl Acad Sci U S A (2002) 1.31
Heterogeneous vascular dependence of tumor cell populations. Am J Pathol (2001) 1.31
Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. Cancer Res (2001) 1.30
Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation (1998) 1.29
Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J (2001) 1.29
Urokinase-dependent plasminogen activation is required for efficient skeletal muscle regeneration in vivo. Blood (2001) 1.25
Cytoglobin expression is upregulated in all tissues upon hypoxia: an in vitro and in vivo study by quantitative real-time PCR. Biochem Biophys Res Commun (2004) 1.22
Development of targeted angiogenic medicine. J Thromb Haemost (2008) 1.22
Intestinal calcium transporter genes are upregulated by estrogens and the reproductive cycle through vitamin D receptor-independent mechanisms. J Bone Miner Res (2003) 1.22
Amine mechanisms in the cerebral circulation. Pharmacol Rev (1976) 1.21
Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. J Clin Invest (1998) 1.20
Blood coagulation factor X deficiency causes partial embryonic lethality and fatal neonatal bleeding in mice. Thromb Haemost (2000) 1.20
Tissue factor expression during human and mouse development. Am J Pathol (1996) 1.19
Hypoxia-inducible factor-2alpha (HIF-2alpha) is involved in the apoptotic response to hypoglycemia but not to hypoxia. J Biol Chem (2001) 1.18
Apoptosis and necrosis after reversible focal ischemia: an in situ DNA fragmentation analysis. J Cereb Blood Flow Metab (1996) 1.17
Chimeric extracellular domain type II transforming growth factor (TGF)-beta receptor fused to the Fc region of human immunoglobulin as a TGF-beta antagonist. Eur J Biochem (1998) 1.16
Cerebral circulation and norepinephrine: relevance of the blood-brain barrier. Am J Physiol (1976) 1.16
Brain kinetics and specific binding of [11C]PK 11195 to omega 3 sites in baboons: positron emission tomography study. Eur J Pharmacol (1991) 1.15
Bmx tyrosine kinase has a redundant function downstream of angiopoietin and vascular endothelial growth factor receptors in arterial endothelium. Mol Cell Biol (2001) 1.15
Disruption of the protein C inhibitor gene results in impaired spermatogenesis and male infertility. J Clin Invest (2000) 1.13
Effects of hemorrhagic hypotension on the cerebral circulation. I. Cerebral blood flow and pial arteriolar caliber. Stroke (1980) 1.13
Effects of decreasing arterial blood pressure on cerebral blood flow in the baboon. Influence of the sympathetic nervous system. Circ Res (1975) 1.13
Up-regulation of a serine protease inhibitor in astrocytes mediates the neuroprotective activity of transforming growth factor beta1. FASEB J (1998) 1.13
Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation (1999) 1.13
Expression of receptors for complement anaphylatoxins C3a and C5a following permanent focal cerebral ischemia in the mouse. Exp Neurol (2000) 1.13
HtrA1-dependent proteolysis of TGF-beta controls both neuronal maturation and developmental survival. Cell Death Differ (2008) 1.13
Upper limit of autoregulation of cerebral blood flow in the baboon. Circ Res (1974) 1.11
A transforming growth factor-beta antagonist unmasks the neuroprotective role of this endogenous cytokine in excitotoxic and ischemic brain injury. J Cereb Blood Flow Metab (1999) 1.11
Neuroprotection mediated by glial cell line-derived neurotrophic factor: involvement of a reduction of NMDA-induced calcium influx by the mitogen-activated protein kinase pathway. J Neurosci (2001) 1.10
Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. II. Evidence for N-methyl-D-aspartate receptor antagonist properties. J Pharmacol Exp Ther (1988) 1.10
Ischemia-induced interleukin-6 as a potential endogenous neuroprotective cytokine against NMDA receptor-mediated excitotoxicity in the brain. J Cereb Blood Flow Metab (2000) 1.10
Reduced transplant arteriosclerosis in plasminogen-deficient mice. J Clin Invest (1998) 1.08
Angiopoietin-1-induced PI3-kinase activation prevents neuronal apoptosis. FASEB J (2003) 1.08
Tissue factor is required for uterine hemostasis and maintenance of the placental labyrinth during gestation. Proc Natl Acad Sci U S A (1999) 1.08
Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. I. Evidence for efficacy in models of focal cerebral ischemia. J Pharmacol Exp Ther (1988) 1.07
Inactivation of the peroxisomal multifunctional protein-2 in mice impedes the degradation of not only 2-methyl-branched fatty acids and bile acid intermediates but also of very long chain fatty acids. J Biol Chem (2000) 1.07
A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules. Mol Cell Neurosci (2008) 1.07
Production of interleukin-6 by folliculo-stellate cells of the anterior pituitary gland in a histiotypic cell aggregate culture system. Neuroendocrinology (1989) 1.06
Complement anaphylatoxin C3a is selectively protective against NMDA-induced neuronal cell death. Neuroreport (2001) 1.06
NR2D-containing NMDA receptors mediate tissue plasminogen activator-promoted neuronal excitotoxicity. Cell Death Differ (2009) 1.05
Serine protease inhibitors: novel therapeutic targets for stroke? J Cereb Blood Flow Metab (2000) 1.05
Reverse glial glutamate uptake triggers neuronal cell death through extrasynaptic NMDA receptor activation. Mol Cell Neurosci (2009) 1.05
Characterization of the vasculogenic block in the absence of vascular endothelial growth factor-A. Blood (2000) 1.05
Migraine and the blood-brain barrier. Lancet (1977) 1.04
Evaluation of the ratio of cerebral blood flow to cerebral blood volume as an index of local cerebral perfusion pressure. Brain (1998) 1.04
Developmental biology. One cell, two fates. Nature (2000) 1.03